Cogent Biosciences (COGT) is back in focus after reporting fourth quarter and full year 2025 results alongside a new shelf registration, while also advancing regulatory filings for its lead drug candidate, bezuclastinib.

The latest earnings, shelf registration and ongoing NDA filings come after a strong run for Cogent Biosciences, with a 1 year total shareholder return of about 4x and an 8.4% 3 month share price return. The recent 3.4% 1 month share price decline suggests some cooling after very strong long term gains.

If Cogent's regulatory progress has your attention, it might be a good moment to see what else is moving in healthcare, starting with our screen of 25 healthcare AI stocks.

With Cogent Biosciences up about 3.7x over the past year and trading around a 40% discount to the current analyst price target, investors now face a key question: is there still a buying opportunity here, or is future growth already priced in?

Preferred Price-to-Book of 29.4x: Is It Justified?

Cogent Biosciences currently trades on a P/B of 29.4x, which is high relative to peers and the broader US Biotechs industry based on Simply Wall St's checks.

The P/B ratio compares a company's market value to the book value of its net assets. For early stage biotech names like Cogent, where revenue is currently $0 and the business is loss making, investors are often paying primarily for future pipeline potential rather than existing assets on the balance sheet.

In Cogent's case, the P/B of 29.4x sits well above both the peer average of 7.2x and the US Biotechs industry average of 2.6x. That spread indicates the market is assigning a much richer valuation multiple than peers. Any future shift in sentiment around trial progress, funding, or profitability expectations could have an outsized impact on how that multiple evolves over time.

Result: Price-to-book of 29.4x (OVERVALUED)

However, you also need to weigh risks, such as Cogent's US$328.937 million net loss and the binary nature of its late stage clinical and regulatory outcomes.

Next Steps

Reading this, you can probably see why views on Cogent are split, with both clear concerns and some upside potential in play. If you want to move quickly and build your own view from the numbers, take a closer look at the 1 key reward and 3 important warning signs that sit behind this story.

Looking for more investment ideas?

If Cogent has sharpened your focus, do not stop here. Broaden your watchlist now so you are not the one hearing about the next big story after the move.

• Target potential value with our screen of 56 high quality undervalued stocks that combines quality fundamentals with prices that may not fully reflect them yet.
• Prioritise resilience by scanning 80 resilient stocks with low risk scores that filter for companies with lower overall risk scores.
• Unearth fresh opportunities using a screener containing 24 high quality undiscovered gems that highlights lesser known names with solid underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.